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Abstract
Background. The local peritoneal effects of low-glucose
degradation product (GDP)-containing peritoneal dialysis
fluid (PDF) have been extensively described. However, the
systemic effects of prolonged prescription of these solu-
tions are unknown. This study aimed to evaluate the effects
of neutral pH and low-GDP PDF on systemic inflammation
and endothelial dysfunction markers in peritoneal dialysis
(PD) patients.
Methods. This is a multicenter, open labeled, randomized
controlled trial including one hundred fifty-two patients
initiating continuous ambulatory peritoneal dialysis for
end-stage renal disease from seven centers in Korea. Partic-
ipants were randomly allocated to conventional PDF (Stay
safe; Fresenius Medical Care, Bad Homburg, Germany)
or low-GDP PDF (Balance; Fresenius Medical Care) and
were followed for 1 year. Primary outcome variable was the
inflammation and endothelial dysfunction index (IEDI),
a composite score derived from serum levels of soluble
intercellular adhesion molecule (sICAM)-1, soluble vascular
cellular adhesion molecule (sVCAM)-1 and high-sensitivity
C-reactive protein (hs-CRP). sICAM-1, sVCAM-1, residual
renal function (RRF), peritoneal membrane transport charac-
teristics, ultrafiltration volume and nutritional parameters
were measured as secondary outcome variables.
Results. Of 152 patients randomized, 146 (low-GDP: con-
ventional PDF, 79:67) patients entered the trial (46% male,
53% with diabetes mellitus). At 12-month follow-up, the
low-GDP group had significantly lower levels of IEDI,
sICAM-1 and sVCAM-1 compared to the conventional
group; hs-CRP was not different between groups. Perito-
neal transport characteristics, RRF, nutritional parameters,
incidence of peritonitis and death-censored technique sur-
vival were not different between groups.
Conclusion. Neutral pH and low-GDP PDF likely produce
fewer changes in markers of endothelial dysfunction com-
pared to conventional PDF in incident PD patients.
Keywords: endothelial dysfunction; glucose degradation products;
inflammation; peritoneal dialysis; soluble adhesion molecules
Introduction
New peritoneal dialysis fluids (PDFs) with neutral pH and
low glucose degradation products (GDPs) are used in pa-
tients on peritoneal dialysis (PD). Low-GDP fluids are re-
ported to be more biocompatible than conventional PDF.
Determination of biocompatibility has mainly focused on
local peritoneal effects; recently, there has been interest in
evaluating the systemic biocompatibility of these fluids.
In recent analyses of two retrospective cohorts of Korean
PD patients, significant survival advantage was shown for
patients treated with the biocompatible PDF compared to
patients treated with the conventional PDF [1, 2]. However,
due to the limitations of an observational study, the mech-
anisms of survival advantage with low-GPD PDF in these
studies are difficult to assess. Additionally, it is not clear
that new PDFs favorably impact risk markers of cardiovas-
cular disease (CVD).
 The Author 2011. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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Epidemiological studies identified an independent asso-
ciation between inflammation and risk of cardiovascular
events and mortality [3]; this association has been con-
firmed in patients with advanced chronic kidney diseases
(CKD) [4, 5]. Other evidence showed that clinically overt
vascular events are preceded by endothelial dysfunction and
increase in circulating markers of endothelial activation, in-
cluding vascular cellular adhesion molecule (VCAM)-1 and
intercellular adhesion molecule (ICAM)-1 [6, 7]. Moreover,
there is an association between inflammation and elevated
levels of soluble VCAM-1 and ICAM-1 in patients with or
at risk of atherosclerosis [8]. Elevated levels of soluble
adhesion molecules are found in end-stage renal disease
(ESRD patients), especially in patients with CVD and mal-
nutrition [9, 10].
A single exposure to GDPs induces VCAM-1 expression
in cultured human peritoneal mesothelial cells [11]. However,
it is not clear whether GDPs directly activate endothelial cells
and increase circulating levels of adhesion molecules or
whether the effect is mediated through the activation of
receptor for advanced glycation end products (RAGE). Of
interest, advanced glycation end products (AGEs) decreased
when patients were converted from standard PDF to low-
GDP PDF [12, 13].
Therefore, we hypothesized that conventional PDF as
well as uremia itself lead to local peritoneal changes such
as peritoneal neoangiogenesis and fibrosis, effects related to
ultrafiltration failure and subsequently volume overload. In
addition, direct effect of GDPs and/or increased systemic
levels of AGEs activate endothelial cells and increase levels
of vascular adhesion molecules and inflammation. Both lo-
cal and systemic effects of PDF are possibly associated with
increased cardiovascular risks and mortality in PD patients.
This study aimed to examine the effects of neutral pH
and low-GDP-containing PDF on systemic inflammation
and endothelial dysfunction markers in incident PD pa-
tients in a randomized controlled study.
Materials and methods
Study design and participants
This is a multicenter, open-labeled, randomized controlled trial of incident
PD patients. It was registered in ClinicalTrials.gov (ClinicalTrials.gov
Identifier: NCT01315314). The study population included PD patients
who initiated dialysis between October 2005 and April 2007 and were
being treated by continuous ambulatory peritoneal dialysis (CAPD). Pa-
tients were recruited from seven centers in South Korea. Patients were
randomly allocated in a 1:1 ratio to conventional PDF (Stay safe; Frese-
nius Medical Care, Bad Homburg, Germany) or low-GDP PDF (Balance;
Fresenius Medical Care) groups and were followed for 1 year. Table 1
reports the composition of each study fluid. Male and female patients aged
>18 years and <75 years who were capable of adhering to prescription
and provided signed informed consent were included. Patients were ex-
cluded if deemed to have <80% likelihood of survival for at least 1 year,
any malignancy other than treated skin carcinoma, uncontrolled conges-
tive heart failure, recent (within 60 days) myocardial infarction or cere-
brovascular accident, active systemic vasculitic disease including systemic
lupus erythematosus, polyarteritis nodosa, Anti-neutrophil cytoplasmic
antibody-nephritis, active rheumatoid disease or active venous throm-
botic-embolic disease, any acute infection at the time of enrollment, active
or actively treated tuberculosis or recent (within 30 days) systemic bacte-
rial infection. The Institutional Review Board at Kyungpook National
University Hospital approved this study and all patients gave written in-
formed consent.
Intervention
Patients were selected when they were scheduled for catheter insertion for
PD. Serum was collected prior to first exposure to PDF and evaluated for
endothelial dysfunction and inflammation including soluble intercellular
adhesion molecule (sICAM)-1, soluble vascular cellular adhesion mole-
cule (sVCAM)-1 and high-sensitivity C-reactive protein (hs-CRP) and
biochemistry data. Before break-in, patients were randomly allocated to
conventional PDF (Stay safe) or low-GDP PDF (Balance) group and
began exchanges with each allocated PDF. After a 4-week run-in period
during which either allocated PDF was used, baseline peritoneal equilibra-
tion test (PET) and biochemical analysis were performed, including the
serum markers mentioned above and advance oxidation protein products
(AOPP) and serum antioxidant capacity. After baseline, PET and bio-
chemical tests were repeated at 6 and 12 months. Primary outcome vari-
able was the inflammation and endothelial dysfunction index (IEDI), a
composite score derived from serum levels of sICAM-1, sVCAM-1 and
hs-CRP. This score is the mean of summative categorical variables derived
from quartiles of each marker at each time point. Secondary outcome
variables were the individual component markers of the IEDI including
sICAM-1, sVCAM-1 and hs-CRP, residual renal function (RRF) as aver-
age of urea and creatinine clearances, peritoneal clearance as weekly Kt/V
urea and creatinine clearance, peritoneal ultrafiltration and peritoneal
transport status by PET. In addition, nutritional indices including serum
albumin, lean body mass (LBM), normalized protein equivalent of nitro-
gen appearance (nPNA) and subjective global assessment (SGA) were
evaluated. Blood pressure (and use of anti-hypertensive medications),
peritonitis rates, technique and patient survival were also assessed.
Clinical assessment
PET was performed using 3.86% glucose dialysis solution as previously
described [15] and peritoneal membrane transport characteristics were
assessed by dialysate-to-plasma creatinine ratio at 4 h of PET. PET was
performed after 4 weeks of peritonitis-free interval when patients were
diagnosed as peritonitis. Total weekly Kt/V urea (Kt/Vurea) and total
weekly creatinine clearance (CCr) were estimated by standard methods.
As nutritional markers, LBM was estimated from creatinine kinetics
using the previously proposed formula [16] and nPNA was calculated as
previously described [17]. SGA with a four item and seven-point scale was
obtained by a trained nurse. RRF was estimated by calculating the average
of residual renal clearances of urea and creatinine. Data on duration of
survival were not based on actual duration of PD but the duration from
baseline visit to the last visit of the study.
Biochemical analysis
sICAM-1 and sVCAM-1 were measured with enzyme-linked immuno-
sorbent assay (R&D systems, Minneapolis, MN) and hs-CRP with high-
sensitivity latex-enhanced immunoturbidimetric assay with MODULAR
P analyzer (Roche Diagnostics, Indianapolis, IN). AOPP and total antiox-
idant activity in serum were measured with AOPP assay kit (Cellbiolabs
Inc., San Diego, CA) and antioxidant kit (Cayman, Ann Arbor, MI),
Table 1. Composition of each study fluida
Low-GDP fluid Conventional fluid
pH 7 5.5
Sodium (mEq/L) 134 134
Calcium (mEq/L) 3.5 3.5
Magnesium (mEq/L) 1 1
Chloride (mEq/L) 101.5 103.5
Lactate (mg/dL) 315.3 315.3
Bicarbonate (mEq/L) 2 0
Glucose (mg/dL)b 1500–4250 1500–4250
3-deoxyglucosone (lmol/L)b 42–60 172–324
Methylglyoxal (lmol/L)b <1 6–10
Acetaldehyde (lmol/L)b <2 152–182
Formaldehyde (lmol/L)b <3 7–13
aNote: values expressed as mean or ranges. Concentrations of GDPs were
derived from reference [14].
bConcentrations in 1.5–4.25% glucose dialysis fluid.
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respectively. Other biochemical analyses were performed using routine
methods at Kyungpook National University Hospital.
Statistical analysis
Sample size was estimated based on the previous report that showed
changes of hs-CRP in PD patients [18]. Estimated sample size of 69 per
arm archives 80% power at a significance level of 0.025 (two-sided) to
detect the differences of 2.6 between the conventional and low-GDP
groups. Assuming 10% of dropout rate and 3% of screening failures, the
study required 79 patients in each group.
Statistical analyses were performed using SPSS version 17.0 (SPSS Inc.,
Chicago, IL) and Sigma Plot version 11 (Systat software Inc., San Jose,
CA). The results are expressed as means and SD. Statistical comparisons
between the groups in baseline characteristics were performed using t-test
or chi-square test. Changes between the groups were tested by analysis of
covariance with baseline values as covariates. Serial data were also ana-
lyzed using a linear mixed model. Survival analysis was done by Kaplan–
Meier survival analysis with log-rank test.
Results
Figure 1 diagrams the study flow. Among the 152 patients
who signed informed consent, 79 were assigned to low-
GDP PDF and 73 to conventional PDF. After allocation,
6 patients from the conventional group were dropped and
146 patients entered baseline PET. Among the 146 patients,
79 in the low-GDP PDF group and 67 in the conventional
group met the specific requirements at the baseline visit. In
total, 122 patients passed Visit 1 at 6 months and 111
patients passed Visit 2 at 12 months. Reasons for dropout
are as follows: in the low-GDP PDF group, one patient trans-
ferred to kidney transplantation, five patients transferred to
hemodialysis, two withdrew consent, two were withdrawn by
an investigator and three died. In the conventional PDF
group, three transferred to kidney transplantation, four trans-
ferred to hemodialysis, nine transferred to non-trial solution,
one was withdrawn by an investigator and two died.
Table 2 reports the baseline characteristics of patients
entering the study. There was no difference between groups
in terms of sex, age and causes of ESRD. Comorbidity
index and body mass index were comparable between the
two groups. Blood pressure at baseline was similar in both
groups. Among the biochemical parameter, all were similar
except serum carbon dioxide (tCO2), which was signifi-
cantly higher in the low-GDP PDF group. Regarding
PET and adequacy data, dialysate-to-plasma ratio of crea-
tinine at 4 h of PET (D4P4cr), at baseline after exposure to
the different solutions during the run-in period, was higher
in the low-GDP PDF group. Total weekly urea clearance
was not different, but peritoneal creatinine clearance was
higher in the low-GDP PDF group. RRF or urine volume
was not different between the two groups. Peritoneal ultra-
filtration volume was lower in the low-GDP PDF group at
baseline in keeping with higher peritoneal transport char-
acteristics in this group. Nutritional markers including se-
rum albumin, LBM, nPNA and SGA and blood pressure
and number of anti-hypertensive medications were not dif-
ferent between the two groups.
Inflammation and endothelial dysfunction markers
After 12 months of PD, IEDI was significantly lower in the
low-GDP PDF group after adjusting for baseline IEDI (Fig-
ure 2). However, we are unable to find any significant time
Fig. 1. Study flow. KT, kidney transplantation; HD, hemodialysis.
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and group effect with linear mixed model analysis. As an
individual endothelial dysfunction marker, sICAM-1 at 12
months was also significantly lower in the low-GDP PDF
group. By linear mixed analysis, it was also significantly
different between the two groups, although we could not find
any significant time effect (Figure 3A). sVCAM-1 was also
significantly lower at 6 and 12 months in the low-GDP PDF
group. The difference was also significant by linear mixed
analysis, but we could not find any significant time effect
(Figure 3B). In contrast to the endothelial dysfunction
markers, level of log-transformed hs-CRP was not different
between the two groups at 12 months. Log-transformed
hs-CRP level at 6 months was slightly higher in the low
GDP PDF group (Figure 3C). AOPP and total antioxidant
capacity were not significantly different between the two
groups (data not shown). In a separate analysis, level of IEDI
and individual component, such as sICAM-1, sVCAM-1 and
log-transformed hs-CRP, were slightly higher in diabetic pa-
tients, but we could not find statistical significance in the
levels of these variables (data not shown).
To evaluate whether conventional PD solution would be
more harmful in patients with active inflammation, we an-
alyzed the interaction between inflammation and solution
group on sICAM-1 and sVCAM-1 at 12 months. In two-
way analysis of variance, there was no interaction effect
between solution group and hs-CRP. Main effect of solu-
tion group controlling for the effect of hs-CRP was signifi-
cant for sICAM-1 (P ¼ 0.012) and sVCAM-1 (P ¼ 0.024),
respectively. Therefore, reduced sICAM-1 and sVCAM-l
levels in the low-GDP PDF group were independent of
baseline hs-CRP (Figure 4A and B).
Dialysis adequacy, peritoneal membrane transport
characteristics, RRF and nutritional status
Table 3 reports the changes in secondary variables. Ad-
equacy data including total Kt/Vurea and creatinine clearance
were not different except peritoneal creatinine clearance at
baseline. Peritoneal creatinine clearance was significantly
higher in the low-GDP PDF group only at baseline, but
changes of adequacy were not different between the two
groups. The change of D4P4cr and peritoneal ultrafiltration
Table 2. Baseline patient characteristics (n ¼ 146)a
Low-GDP fluid
(n ¼ 79)
Conventional
fluid (n ¼ 67)
Sex (male, %) 37 (46.8%) 30 (44.8%)
Age (years) 52.2 6 11.4 52.6 6 11.1
Cause of ESRD (n, %)
DM 40 (50.6%) 27 (40.3%)
HTN 23 (29.1%) 28 (41.8%)
CGN 10 (12.7%) 4 (6.0%)
Others/unknown 6 (7.6%) 8 (11.9%)
Comorbidities
DM (n, %) 41 (51.9%) 37 (55.2%)
CAD (n, %) 6 (7.6%) 1 (1.5%)
Modified Charlson’s
comorbidity index
4.06 6 1.56 3.99 6 1.58
Weight (kg) 59.1 6 9.2 57.9 6 9.2
BMI (kg/m2) 22.9 6 3.2 22.6 6 2.6
Blood pressure (mmHg)
SBP 131.6 6 19.3 131.4 6 20.8
DBP 82.2 6 11.9 81.3 6 12.1
Use of ACEi or ARB (%) 65.8% 78.1%
Biochemistry
Hb (g/dL) 11.1 6 1.5 10.8 6 1.7
Serum creatinine (mg/dL) 7.3 6 2.8 7.2 6 2.6
Cholesterol (mg/dL) 189.6 6 47.1 191.4 6 50.1
Triglyceride (mg/dL) 131.1 6 73.8 169.3 6 189.9
Ca (mg/dL) 8.7 6 0.7 8.8 6 0.9
P (mg/dL) 4.6 6 1.3 4.7 6 1.3
tCO2 (mEq/L) 25.0 6 3.7* 23.7 6 3.4
Urinary protein (mg/day) 1700 6 2000 2000 6 2100
PET and adequacy
D4/P4 creatinine 0.74 6 0.12* 0.69 6 0.12
Kt/Vurea 2.4 6 0.6 2.3 6 0.6
Kpt/Vurea 1.7 6 0.4 1.7 6 0.5
Krt/Vurea 0.8 6 0.5 0.7 6 0.5
CrCl (L/week/1.73m2) 84.1 6 30.9 77.5 6 27.9
Kpcr 41.4 6 7.3* 37.9 6 6.9
Ccr 38.9 6 31.3 36.0 6 26.2
RRF (mL/min) 3.9 6 3.1 3.7 6 2.6
Ultrafiltration volume (mL)
Total fluid removal (mL/day) 1479 6 762 1636 6 586
Peritoneal fluid removal (mL/day) 621 6 520* 962 6 527
Urine volume (mL/day) 880 6 732 717 6 536
Peritoneal ultrafiltration per
glucose load (mL/g glucose)
5.69 6 5.04* 9.54 6 4.73
Nutritional markers
Serum albumin (g/dL) 3.6 6 0.6 3.6 6 0.5
LBM (kg) 37.5 6 9.7 35.1 6 8.6
nPNA (g/kg/day) 0.91 6 0.18 0.90 6 0.25
SGA 5.9 6 1.2 5.7 6 1.1
aNote: data are shown as mean 6 SD. Bold indicates the parameters have
significant differences between the two groups and asterisk indicates p <
0.05 versus conventional fluid group. DM, diabetes mellitus; HTN, hyper-
tension; CGN, chronic glomerulonephritis; CAD, coronary artery disease;
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood
pressure; ACEi, angiotensin-converting enzyme inhibitor; ARB, angioten-
sin II receptor blocker; tCO2, total carbon dioxide in serum; PET, peri-
toneal equilibration test; D4/P4 creatinine, dialyzate-to-plasma creatinine
ratio at 4 h of PET; Kt/Vurea, total weekly urea clearance; Kpt/Vurea,
peritoneal urea clearance; Krt/Vurea, renal urea clearance; CrCl, total crea-
tinine clearance; Kpcr, peritoneal creatinine clearance; Ccr, renal creati-
nine clearance; RRF [mean of creatinine clearance (Ccr) and urea
clearance (Curea)].
Fig. 2. Changes of IEDI. Gray bar denotes low-GDP group and white bar
conventional group. In box plots, horizontal lines at the top, middle and
bottom of the boxes show the 75th, 50th and 25th percentiles, respectively,
and vertical lines above and below the boxes show the 90th and 10th
percentiles, respectively. The lower and upper circles show the 95th and
5th percentiles, respectively. *P < 0.05 versus conventional group by
analysis of covariance. In linear mixed model analysis, P ¼ 0.156 for time
effect and P ¼ 0.147 for group effect.
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volume per glucose loading was significantly different
between the two groups by linear mixed model analysis
(Figure 5A and B). However, the change of RRF (Figure
5C) or urine volume was not different between the two
groups. The change of nutritional markers including serum
albumin, LBM, nPNA and SGA was not different between
the two groups. In addition, changes in blood pressure and
number of anti-hypertensive medications were not different
between the two groups.
Peritonitis and survival
Total peritonitis incidence was 46 episodes of peritonitis
per 1550 patient-months. Mean follow-up period of PD
Fig. 3. Changes of sICAM-1 (A), sVCAM-1 (B) and log-transformed hs-CRP (C). Gray bar denotes low-GDP group and white bar conventional group.
*P < 0.05 versus conventional group by analysis of covariance. In linear mixed model analysis, P ¼ 0.928 (time), P ¼ 0.003 (group) for sICAM-1 (A),
P ¼ 0.117 (time), P ¼ 0.006 (group) for sVCAM-1 (B) and P ¼ 0.504 (time), P ¼ 0.007 (group) for log-transformed hs-CRP (C).
Fig. 4. Effect of inflammation and solution group on sICAM-1 (A) and sVCAM-1 (B) at 12 months of PD. hs-CRP group was divided by median value
of hs-CRP level before PD start. Main effect of solution group controlling for the effect of hs-CRP was significant. P ¼ 0.012 (sICAM-1, A) and
P ¼ 0.024 (sVCAM-1, B), respectively.
Effect of GDPs on endothelial dysfunction 1195
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was 11.0 versus 10.1 months for the low-GDP PDF and
conventional PDF groups, respectively. Frequency of peri-
tonitis was not different between the two groups (one
episode per 34.8 versus 32.3 patient-months for low-GDP
PDF and conventional PDF groups, respectively). During
follow-up of 12 months, five deaths were reported. In sur-
vival analysis, patient survival and death-censored technique
survival were not different between the two groups (Figure
6A and B).
Discussion
This is the first prospective, randomized controlled study
investigating inflammation and endothelial dysfunction
markers as primary outcomes in incident PD patients
exposed to different levels of GDP-containing PDF. Our
study demonstrates that endothelial dysfunction markers
were significantly lowered in PD patients exposed to
low-GDP PDF compared to standard PDF after 12 months
of PD.
The local peritoneal effects of low-GDP PDF are well
known from previous studies, showing improvement of
peritoneal effluent markers of peritoneal integrity, such as
CA125 or hyaluronic acid [12, 19]. Consistently, animal
models of PD demonstrate fewer structural alterations in
the local peritoneum, such as peritoneal inflammation, neo-
angiogenesis and fibrosis, with low GPD PDF compared to
standard PDF [20]. In addition to its local effects, the sys-
temic effects of low-GDP PDF were partly reported in
previous studies, showing lower concentration of systemic
AGEs and/or C-reactive protein levels in low-GDP PDF-
treated patients [12, 13, 18, 19]. AGEs are commonly seen
in patients with CKD; their production is promoted by
oxidative and carbonyl stress. The levels of systemic AGEs
were more markedly elevated after exposure to conven-
tional PDF compared to low-GDP PDF [21]. Interestingly,
the levels of selected AGEs decrease when patients are
converted from standard PDF to low-GDP PDF [12, 13,
22]. AGEs activate inflammatory cells and directly stimu-
late endothelial cells to express adhesion molecules [23].
Certain subtypes of AGEs activate monocytes, which have
important pathogenic roles in the progression of atheroscle-
rosis, and subsequently increase production of adhesion
molecules and cytokines [24]. Vascular adhesion mole-
cules, such as sVCAM-1 or sICAM-1, are known biochem-
ical markers of endothelial dysfunction [25]. Endothelial
dysfunction was partly mediated by AGEs-induced inhib-
ition of nitric oxide synthase through receptor for AGE
(RAGE) [26]. In addition, elevated levels of soluble adhe-
sion molecules are found in CKD patients, especially in
malnourished, inflamed patients and patients with CVD
[9, 10]. Clinically overt vascular events are reportedly pre-
ceded by endothelial dysfunction [27]. Endothelial dys-
function and inflammation are suggested to be novel risk
markers, in addition to other uremia-related factors, and
they act synergistically with the highly prevalent traditional
risk factors for CVD in the CKD population.
In this study, we observed less elevation of vascular ad-
hesion molecules in patients receiving low-GDP PDF. This
might be associated with a reduction in elevation of sys-
temic AGEs in patients treated with low-GDP PDF. In ad-
dition, indirect evidence, such as induced VCAM-1
expression in cultured human peritoneal mesothelial cells
following a single exposure to GDPs [11], suggests a direct
effect of GDP on vascular endothelial cells. However, there
is currently a paucity of scientific evidence supporting a
direct effect of GDPs on vascular endothelial cell activation.
Table 3. Changes in secondary outcome variablesa
Period
Baseline 6 months 12 months
Group Low-GDP Conventional Low-GDP Conventional Low-GDP Conventional
Kt/Vurea 2.4 6 0.6 2.3 6 0.6 2.2 6 0.5 2.3 6 0.7 2.2 6 0.6 2.1 6 0.7
Kpt/Vurea 1.7 6 0.4 1.7 6 0.5 1.5 6 0.4 1.6 6 0.4 1.6 6 0.5 1.8 6 1.1
Krt/Vurea 0.8 6 0.5 0.7 6 0.5 0.7 6 0.5 0.6 6 0.6 0.5 6 0.5 0.5 6 0.6
CrCl (L/week/1.73m2) 84.1 6 30.9 77.5 6 27.9 74.8 6 25.6 74.4 6 28.1 67.9 6 24.4 68.6 6 28.7
Kpcr 41.4 6 7.3* 37.9 6 6.9 38.0 6 7.3 40.4 6 8.0 38.8 6 9.3 39.9 6 8.6
Ccr 38.9 6 31.3 36.0 6 26.2 33.1 6 25.7 29.0 6 28.0 25.9 6 23.4 24.3 6 30.3
RRF (mL/min) 3.9 6 3.1 3.7 6 2.6 3.4 6 2.5 3.1 6 2.8 2.9 6 2.3 2.9 6 3.1
Total fluid removal (mL/day) 1479 6 762 1636 6 586 1440 6 512 1659 6 665 1469 6 721 1459 6 646
Peritoneal fluid removal (mL/day) 621 6 520* 962 6 527 673 6 522* 1045 6 600 845 6 633 939 6 683
Urine volume (mL/day) 880 6 732 717 6 536 803 6 513 677 6 568 714 6 537 644 6 575
Peritoneal UF per glucose load
(mL/g glucose)
5.69 6 5.04* 9.54 6 4.73 6.29 6 5.60* 9.69 6 5.47 7.92 6 5.86 8.72 6 6.68
Serum albumin (g/dL) 3.6 6 0.6 3.6 6 0.5 3.7 6 0.6 3.7 6 0.5 3.7 6 0.6 3.7 6 0.4
LBM (kg) 37.5 6 9.7 35.1 6 8.6 38.7 6 10.0 37.5 6 8.4 39.7 6 11.1 37.8 6 9.2
nPNA (g/kg/day) 0.91 6 0.18 0.90 6 0.25 0.88 6 0.18 0.91 6 0.18 0.88 6 0.19 0.89 6 0.21
SGA 5.9 6 1.2 5.7 6 1.1 6.0 6 1.3 5.8 6 1.1 6.0 6 1.4 5.9 6 1.3
Blood pressure (mmHg)
SBP 131.6 6 19.3 131.4 6 20.8 132.0 6 16.8 132.5 6 21.7 134.5 6 20.8 129.6 6 19.3
DBP 82.2 6 11.9 81.3 6 12.1 82.2 6 9.9 80.9 6 12.6 82.5 6 11.3 81.2 6 11.3
Anti-hypertensive agents (numbers) 2.2 6 0.8 2.2 6 0.8 2.1 6 0.7 2.2 6 0.9 2.3 6 0.9 2.4 6 1.0
aNote: data are shown as mean6 SD. Bold indicates the parameters have significant differences between the two groups and asterisk indicates p < 0.05
versus conventional fluid group. Kt/Vurea, total weekly urea clearance; Kpt/Vurea, peritoneal urea clearance; Krt/Vurea, renal urea clearance; CrCl, total
creatinine clearance; Kpcr, peritoneal creatinine clearance; Ccr, renal creatinine clearance; RRF [mean of creatinine clearance (Ccr) and urea clearance
(Curea)]; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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Fig. 5. Changes of dialysate-to-plasma ratio of creatinine (D4/P4cr) (A), peritoneal ultrafiltration (UF) volume per glucose load (mL/g glucose)
(B) and RRF (mL/min) (C). Closed circle denotes low-GDP group and open circles conventional group. *P < 0.05 versus, conventional group by
analysis of covariance. P ¼ 0.194 (time), P ¼ 0.002 (group) for D4/P4cr (A), P ¼ 0.518 (time), P ¼ 0.003 (group) for UF/glucose (B) and P ¼ 0.309
(time), P ¼ 0.589 (group) for RRF (C).
Fig. 6. Survival analyses for patients (A) and technique survival (B). Solid line denotes low-GDP group and dashed line conventional group. In log-rank
test, P ¼ 0.849 and 0.928, respectively.
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Besides soluble adhesion molecules, however, we were
unable to demonstrate significant differences in inflamma-
tion and oxidative stress markers between the two treatment
groups. In this study, hs-CRP was not significantly differ-
ent between the two groups after 12 months of PD. This is
in contrast to previous reports, which found lower hs-CRP
in the low-GDP groups in prevalent and incident PD
patients [18, 19].
We could not explain exactly how this difference in the
changes of hs-CRP occurs in our study. However, we assume
that a higher level of hs-CRP at baseline, even though it is not
statistically significant, may affect the change of hs-CRP, at
least, at 6 months. Moreover, from an other point of view, if
the low-GDP solution harmfully affects hs-CRP levels be-
yond 6 months, the difference would be more prominent at
12 months. However, we could not find a significant differ-
ence of hs-CRP at 12 months.
In a retrospective analysis of Korean PD patients, use of
bicarbonate/lactate, low-GDP PDF is associated with im-
provement in overall patient survival [2]. However, it is not
clear whether the favorable effect of low-GDP PDF is di-
rectly linked to the improvement of cardiovascular out-
comes in PD patients. Based on our results, changes in
vascular adhesion molecules as a marker of endothelial
dysfunction, in addition to surrogate markers for cardiovas-
cular outcomes in PD patients, may provide evidence of
cardiovascular effects.
Considering secondary outcome variables, we found higher
peritoneal membrane transport characteristics in the low-GDP
group at baseline. During the run-in period before baseline
PET, patients were already exposed to different dialysis
solutions for at least 4 weeks; thus, peritoneal membrane
transport characteristics might be affected by a different
PDF. Similarly, the Eurobalance trial [12] reported higher
peritoneal membrane transport in the low-GDP group after
12 weeks of PDF exposure. In addition, in this study, peri-
toneal ultrafiltration volume was significantly lowered until
6 months of PD without difference in RRF. Change of urine
volume was not significantly different between the two treat-
ment groups. Therefore, differences in peritoneal ultrafiltra-
tion volume may be associated with peritoneal membrane
transport characteristics rather than RRF in our study. The
effects of low-GDP fluid on RRF were not consistent in
several studies, with some reporting protective effects
[12,28] and others finding no influence [19]. Similar to
our study, changes of RRF and urine volume were not
statistically different between the incident PD patients (in-
cluding automated PD) treated with biocompatible PDF
and standard PDF in a randomized controlled trial of 1-year
[29]. However, in an another 1-year of randomized study in
incident CAPD patients, low-GDP PDF was beneficial for
maintaining RRF, especially in patients with a GFR of
2 mL/min/1.73m2 [30]. This may be related to variations
in compounding factors affecting RRF as well as popula-
tion of patients.
Peritonitis incidence, expressed as episodes per
patient-months, was not different between the two groups.
This is consistent with previous studies with low-GDP
PDF. Moreover, the data for survival analysis were
also consistent with a previously reported randomized
study [19].
Some limitations of this study should be noted. We
measured endothelial dysfunction only by biomedical
markers not by functional endothelial dysfunction due to
the limitation of standard instruments and procedures in
different multiple centers. Previous reports show that flow-
mediated vasodilatation, a commonly used method for en-
dothelial dysfunction, correlates with levels of vascular
adhesion molecules [31,32]. This indicates that vascular
adhesion molecules could be a useful biomarker for func-
tional endothelial dysfunction. Secondly, in this multicen-
ter study, center effect was not fully adjusted. We assumed
minimal center effect because all centers have similar char-
acteristics regarding the PD program. In addition, allocation
of patients was performed randomly at each center. All
seven centers participating in this randomized study have
experienced PD-oriented doctors with >100 PD patients
for five centers and 40 patients for two centers. Lastly,
the number of patients in both groups was not completely
balanced when entering baseline study period because of
higher drop rate during the run-in period for the conven-
tional PDF group. This may lead to a selection bias.
In conclusion, neutral pH and low-GDP PDF likely have
a beneficial effect on endothelial dysfunction markers com-
pared to standard PDF in incident PD patients, although the
association of these surrogate outcome markers and long-
term clinical outcomes of low GDP PDF needs to be eval-
uated in further studies.
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